Why Americans’ access to lifesaving vaccines is threatened by RFK Jr. overhaul

By Michelle Amponsah Damian Garde and Denise Lu Bloomberg Healthcare and Human Services Secretary Robert F Kennedy Jr s changes to US vaccine procedures are putting the billion US territory for shots at hazard potentially making it harder for Americans to access them RELATED Kennedy s new vaccine panel alarms pediatricians with inquiries into long-settled questions The leader of the Kennedy-appointed panel explained it will reconsider the cabinet s recommendations for childhood vaccines and take another look at any shots that haven t been examined in the last seven years It was an unexpected move from a panel that normally discusses topics like flu shot effectiveness and came Wednesday during its first gathering since the group was revamped The two-day meeting drew thousands of watchers and could have sweeping implications for vaccines in the US The panel known as the Advisory Committee on Immunization Practices has historically influenced which shots are given when and vitally whether they get broad insurance coverage Changing federal recommendations could alter the routine curative care of for millions of people around the country Earlier this month Kennedy fired every member of the panel and named eight replacements including particular who have espoused discredited theories about vaccine safety One new member Michael Ross stepped down during the financial holdings review required of members before they can start according to an HHS spokesperson The revamped panel has already stoked a backlash Senator Bill Cassidy a Louisiana Republican who voted to confirm Kennedy after securing a promise he wouldn t change the lineup of ACIP experts had unsuccessfully called for the panel to delay the meeting out of concern the new members weren t qualified On Wednesday he questioned why the committee wasn t getting any details showing the vaccine preservative thimerosal was safe something that is widely accepted by the anatomical establishment Committee chairman Martin Kulldorff a biostatistician who announced he was fired by Harvard University after refusing to take a Covid vaccine used his opening remarks Wednesday to defend his fellow panelists and insist the group had a clear mandate to use evidence-based medicine in its recommendations Particular media outlets have been very harsh on the new members of this committee issuing false accusations and making concerted efforts to put scientists in either a pro- or anti-vaccine box Kulldorff explained Such labels undermine critical scientific inquiry and it further feeds the flames of vaccine hesitancy If the panel ultimately reverses past decisions it would change the calculus for companies that manufacture vaccines Shots that lose the stamp of approval from ACIP may become too financially risky to manufacture according to general vitality experts and investors Its actions are being closely watched More than people tuned into a webcast of the meeting which traditionally draws little attention The group is also debating whether to back Merck Co s shot to prevent RSV in newborns and digging into a little-used vaccine preservative falsely linked to childhood autism One of ACIP s newly informed working groups will consider whether hepatitis B vaccines are given too early Kulldorff noted Infants at this moment get it within hours of birth to prevent transmission from an infected mother who may not know if she has it according to the Centers for Syndrome Control and Prevention The decisions of the revamped panel could influence whether companies manufacture vaccines are insulated from lawsuits over side effects Revoking recommendations for the shots would almost certainly make them harder to come by ending a decades-long era in the US of affordable and plentiful lifesaving vaccines It s major for everyone to realize there will be no vaccines if there are no vaccine manufacturers commented James Campbell who has represented the American Academy of Pediatrics at ACIP meetings People can critique the manufacturers and there are reasonable critiques but there is nobody else to make vaccines if we don t have vaccine manufacturers Lawsuit Protection Current US vaccine guidelines dates back to the s Then a now-debunked documentary about the prospective side effects of the combined diphtheria whooping cough and tetanus shot that aired on TV led to a wave of lawsuits against manufacturers Companies curtailed production and the US struggled with shortages Congress then created the National Vaccine Injury Compensation Plan to shield companies from the financial liability of lawsuits It includes a taxpayer-backed fund to help patients who experience damaging vaccine side effects For a vaccine to be covered by the fund it has to be recommended by the CDC for children or pregnant people The CDC typically bases those recommendations on the advice of ACIP which reviews the science of each shot Recommendations made by ACIP are generally adopted by the CDC director to become the agency s official initiative President Donald Trump s nominee for the job Susan Monarez sat before the Senate Healthcare Schooling Labor and Pensions Committee in a confirmation hearing during the morning as ACIP met Normally ACIP members undergo an extensive vetting process and have a background in immunizations The current members have relatively little scientific background in vaccines and include one self-proclaimed anti-vaxxer Kennedy noted he made the strange decision to remove all former members and appoint new ones to reestablish population confidence in vaccine science The new members will be reviewing shots the CDC already supports They are expected to vote on recommendations for vaccines containing thimerosal a mercury-containing preservative that is used in about of flu vaccines That would possibly affect products already on the territory from Sanofi SA and CSL Ltd Community healthcare and legal experts have conflicting views about whether those shots would straightaway lose their liability protection if the new ACIP panel votes against them Dorit Reiss a law professor at the University of California at San Francisco revealed they would However Richard Hughes IV a lawyer at Epstein Becker Green PC and former Moderna Inc executive declared it would take time for the change to happen The removal of financial protections for manufacturers would make it demanding for companies to invest reported Jeff Jonas a portfolio manager at Gabelli Funds I think companies are going to be hesitant or even unlikely to start new vaccine programs he mentioned You have to be really confident in the device and the sector size and the ability to afford a larger and longer randomized clinical trial to get it to territory Kennedy has been a strong critic of the vaccine injury fund saying it removes the financial incentive for drugmakers to make vaccines safer He also has the ability to reject the advice of ACIP and the CDC if he doesn t like it which he already did with Covid shots for healthy children and pregnant people Adding to the tough setting ACIP recommendations affect how insurance will pay out Typically when the panel calls for a shot the CDC director and HHS secretary agree with that assessment That leads to insurers fully covering the vaccines and the federal regime providing them to families who can t afford them through the Vaccines for Children Operation About half of kids in the US are eligible for taxpayer-funded shots Widespread coverage provides another financial incentive for manufacturers to make vaccines Earlier this month several insurers revealed they were monitoring changes in ACIP recommendations So much of our vaccine agenda nationally and at the state level really is automatically tied to these recommendations declared Hughes the former Moderna executive and lawyer The vast majority of Americans have vitality insurance coverage that is dependent on these recommendations With assistance from Jessica Nix Rachel Cohrs Zhang and Gerry Smith More stories like this are available on bloomberg com Bloomberg L P